Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.

Pharmacogenomics - 1 Feb 2014

Spinasse Lizania Borges, Santos Adalberto Rezende, Suffys Philip Noel, Muxfeldt Elizabeth Silaid, Salles Gil Fernando

Abstract excerpt

AIM: Hydralazine, a vasodilator used in resistant hypertension (RH) treatment is metabolized by an acetylation reaction mediated by N-acetyltransferase 2, the activity of which depends on NAT2 polymorphisms. Our aim was to evaluate whether different acetylation phenotypes influenced the antihypertensive effect of hydralazine in patients with RH. PATIENTS & METHODS: DNA samples from 169 RH patients using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antihypertensive Agents

Share to Arylamine N-Acetyltransferase

Share to Blood Pressure

Share to Hypertension

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 24444407
DOI: 10.2217/pgs.13.202

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.PMID 24444407Read ↗

Genotype-Guided Hydralazine TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.Semantic proximity Read ↗

N-Acetyltransferase 2 Genotype-Dependent N-Acetylation of Hydralazine in Human Hepatocytes.Semantic proximity Read ↗

Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.Semantic proximity Read ↗

Acetylation phenotype in hypertensive patients.Semantic proximity Read ↗

NAT2 sequence polymorphisms and acetylation profiles in Indians.Semantic proximity Read ↗

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.Semantic proximity Read ↗

Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs.Semantic proximity Read ↗

Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.Semantic proximity Read ↗

Plasma concentration and acetylator phenotype determine response to oral hydralazine.Semantic proximity Read ↗

Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.Semantic proximity Read ↗

Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.